Possible involvement of nitric oxide (NO) signaling pathway in the anti-depressant-like effect of MK-801(dizocilpine), a NMDA receptor antagonist in mouse forced swim test

Indian Journal of Experimental Biology

Volumn 46, Issue 3, 2008, Pages 164-170

  Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Cyclic guanosine monophosphate; Forced swim test; L arginine; MK 801 (dizocilpine); Nitric oxide; Phosphodiesterase 5 inhibitor

Indexed keywords

MUS;

ANTIDEPRESSANT AGENT; ARGININE; CYCLIC GMP; DIZOCILPINE MALEATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EXERCISE; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SWIMMING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; CYCLIC GMP; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERTION; MICE; NITRIC OXIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; SWIMMING;

EID: 45149118638     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Paul I A & Skolnick P, Glutamate and Depression, Ann NY Acad Sci, 1003 (2003) 250.
2. Rada P, Moreno S A, Tucci S, Gonzalez I E, Harrison T, Chau D T, Hoebel B G & Hernandez L, Glutamate release in the nucleus accumbens is involved in behavioral depression during the porsolt swim test, Neuroscience, 119 (2003) 557.
3. Papp M & Moryl E, Antidepressant activity of noncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression, Eur J Pharmacol, 263 (1994) 1.
4. Kos T, Legutko B, Danysz W, Samoriski G & Popik P, Enhancement of antidepressant-like effects but not brainderived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice, J Pharmacol Exp Ther, 318 (2006) 1128.
5. Berman R M, Cappiello A, Anand A, Oren D A, Heninger G R, Charney D S & Krystal J H, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47 (2000) 351.
6. Wong E H, Kemp J A, Priestley T, Knight A R, Woodruff G N, Iversen L L, The anticonvulsant MK-801 is a potent Nmethyl- D-aspartate antagonist, Proc Natl Acad Sci USA, 83 (1986) 7104.
7. Ayala G X & Tapia R, N-methyl-D-aspartate receptor blockade rescues hippocampal neurons from excitotoxic stress and death after 4-aminopyridine- induced epilepsy, Eur J Neurosci, 22 (2005) 3067.
8. Kocaeli H, Korfali E, Ozturk H, Kahveci N & Yilmazlar S, MK-801 improves neurological and histological outcomes after spinal cord ischemia induced by transient aortic crossclipping in rats, Surgical Neurology, 64 (2005) S22.
9. Mukhin A G, Ivanova S A, Knoblach S M & Faden A I, New in vitro model of traumatic neuronal injury: Evaluation of secondary injury and glutamate receptor-mediated neurotoxicity, Neurotrauma, 14 (1997) 651.
10. Maj J, Rogoz Z & Skuza G, The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats, Polish Pharmacol, 44 (1992) 217.
11. Mantovani M, Pertile R, Calixto J B, Santos A R & Rodrigues A L, Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the Larginine- nitric oxide pathway, Neurosci Lett, 343 (2003) 1.
12. Esplugues J V, NO as a signalling molecule in the nervous system, Brit J Pharmacol, 135 (2002) 1079.
13. Joca S R & Guimaraes F S, Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects, Psychopharmacology (Berl), 185 (2006) 298.
14. Kaster M P, Ferreira P K, Santos A R S & Rodrigues A L S, Effect of potassium channel inhibitors in the forced swimming test: Possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway, Behavioural Brain Res, 165 (2005) 204.
15. Contestabile A, Roles of NMDA receptor activity and nitric oxide production in brain development, Brain Res Rev, 32 (2000) 476.
16. Almeida R C, Felisbino C S, Lopez M G, Rodrigues A L S & Gabilan N H, Evidence for the involvement of L-argininenitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice, Behavioural Brain Res, 168 (2006) 318
17. Dhir A & Kulkarni S K, Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice, Prog Neuropsychopharmacology Biological Psychiatry, 31 (2007) 921.
18. Dhir A & Kulkarni S K, Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion a dopamine reuptake inhibitor, Eur Pharmacol, 568 (2007) 177.
19. Dhir A & Kulkarni S K, Involvement of Dopamine (DA)/serotonin (5-HT)/Sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride a D2/D3 dopamine receptor agonist, Brain Research Bulletin, 74 (2007) 58.
20. Porsolt R D, Anton G, Blavet N & Jalfre M, Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur Pharmacol, 47 (1978) 379.
21. Kulkarni S K & Dhir A, Possible involvement of LArginine- nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride, Eur Pharmacol, 569 (2007) 77.
22. Kulkarni S K & Dhir A, Effect of various classes of antidepressants in behavioural paradigms of despair, Prog Neuropsychopharmacology Biological Psychiatry, 31 (2007) 1248.
23. Kulkarni S K & Mehta A K, Purine nucleoside-mediated immobility in mice: reversal by antidepressants, Psychopharmacology (Berl) 85 (1985) 460.
24. Parale M P & Kulkarni S K, Clonidine-induced behavioural despair in mice: Reversal by antidepressants, Psychopharmacology, 89 (1986) 171.
25. Reddy DS, Kaur G & Kulkarni SK, Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test, Neuroreport, 9 (1998) 3069-3073.
26. Dhir A & Kulkarni S K, Involvement of sigma (σ1) receptors in modulating the antidepressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse tailsuspension test, Psychopharmacol, (In Press).
27. Dhir A, Naidu P S & Kulkarni S K, Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawalinduced behavioral changes, Addiction Biology, 10 (2005) 329.
28. Patil C S, Singh V P & Kulkarni S K, Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil, Inflammopharmacology, 13 (2005) 467.
29. Harkin A, Connor T J, Burns M P & Kelly J P, Nitric oxide inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test, Eur Neuropsychopharmacol, 14 (2004) 274.
30. Heiberg I L, Wegener G & Rosenberg R, Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats, Behavioural Brain Res, 134 (2002) 479.
31. Harkin A, Connor T J, Walsh M, St John N & Kelley J P, Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors, Neuropharmacology, 44 (2003) 616.
32. Wegener G, Volke V, Harvey B H & Rosenberg R, Local but not systemic administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity, Brain Res, 959 (2003) 128.
33. Ergun Y & Ergun U G, Prevention of pro-depressant effect of l-arginine in the forced swim test by N(G)-nitro-l-arginine and [1H-[124]Oxadiazole[43-a]quinoxalin-1-one], Eur Pharmacol, 554 (2007)150.
34. Singh V P, Jain N K & Kulkarni S K, Fluoxetine suppresses morphine tolerance and dependence: modulation of NOcGMP/DA/serotoninergic pathways, Methods Find Exp Clin Pharmacol, 25 (2003) 273.
35. Volke V, Wegener G, Bourin M & Vasar E, Antidepressantand anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2- trifluoromethylphenyl)-imidazole in mice, Behav Brain Res, 140 (2003) 141.
36. Eroglu L & Caglayan B, Anxiolytic and antidepressant properties of methylene blue in animal models, Pharmacol Res 36 (1997) 381.
37. Belozertseva I V, Kos T, Popik P, Danysz W & Bespalov A Y, Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests, Eur Neuropsychopharmacol, 17 (2007) 172.
38. Kulkarni S K & Patil C S, Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects, Methods Find Exp Clin Pharmacol, 26 (2004) 789.
39. Denninger J W & Marletta M A, Guanylate cyclase and the NO/cGMP signaling pathway, Biochim Biophys Acta, 1411 (1999) 334.
40. Bender A T & Beavo J A, Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages, Neurochemistry International, 45 (2004) 853.